Introgen Presents Latest Research Findings at ASCO
(PR Newswire)...CNBC(TM) and CNNfn(TM) upon news that Introgen`s compound INGN 241, in a preclinical study, demonstrated anti-tumor effects in three prevalent human cancers: breast, lung and colorectal.......Introgen is also conducting a Phase II clinical trial for INGN 201 in lung cancer and Phase I trials for INGN 201 in additional cancer indications including prostate, ovarian, bladder, brain, and breast cancer.......INGN 241 (Adenoviral-mda7), for the treatment of solid tumors, is in Phase I clinical development....- May 11 10:47 AM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/010511/daf013.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines